A platform leveraging AI to analyze single-cell RNA data for identifying novel targets in solid tumors.

Tool: Phenomic AI
Description: A platform leveraging AI to analyze single-cell RNA data for identifying novel targets in solid tumors.
Summary: Phenomic AI specializes in using advanced machine learning to process imaging, RNA sequencing, and spatial transcriptomics data, focusing on the intricate biology of single cells within complex multicellular systems. Their platform is designed to explore cell type and target expression profiles in great detail, aiding in the discovery of novel therapeutic targets for solid tumors. This approach enables the identification of high-impact, druggable targets, demonstrating the platform's potential in addressing challenging cancers.
Category: Drug Discovery
Tags: Precision Medicine, Genomics
Use Cases: Identifying novel therapeutic targets for challenging solid tumors like colorectal and pancreatic cancers.; Exploring cell type and target expression profiles in human cancer and normal tissue samples.
Platform: Web
Vendor: Phenomic AI Inc.
Target Users: Researcher
Pricing: not for sale
Regulatory: not a medical device
Meta: Phenomic AI uses machine learning to analyze single-cell RNA data, aiding in the discovery of novel targets for solid tumor treatment.
Content: [![Phenomic AI](https://phenomic.ai/img/nav-logo.png)](https://phenomic.ai/#) - [Home](https://phenomic.ai/#) - [Approach](https://phenomic.ai/#papers) - [Platform](https://phenomic.ai/#approach) - [Team](https://phenomic.ai/#team) - [News](https://phenomic.ai/#news) - [Careers](https://phenomic.ai/#careers) - [Contact](https://phenomic.ai/#contact) # Targeting Tumor Biology Our mission is to raise the survival curve for the hardest to treat solid tumors. [Learn More](https://phenomic.ai/#approach) ![](https://phenomic.ai/img/cell-cell.png) Single-cell data from human tissues **is providing unprecedented detail** into target expression and selectivity. ![](https://phenomic.ai/img/convolutional-net.png) Our platform **interrogates single-cell RNA data at scale** and is currently focused on solid tumors. ![](https://phenomic.ai/img/antibodies.png) Understanding the biology of tumors as whole systems unlocks **powerful new therapeutic approaches**. ![](https://phenomic.ai/img/stroma.jpg) ### Phenomic's Approach Despite recent advances, outcomes for most solid tumor patients remain poor (e.g., colorectal, pancreatic, breast cancers). We believe the reason why drugs for these cancers have not translated well in the clinic historically is that they were largely discovered and studied in models that do not account for the diversity of cell types present in human tumors. To address this challenge, we have built an ML-powered transcriptomics platform that allows us to understand the interactions of all the cell types in these tumors to identify compelling targets and a system to test our drugs in human tumor explants thus delivering translational insights during our discovery process. Our lead program is a CD3 engager that uses a novel targeting approach identified by our platform that should be able to overcome limitations of traditional tumor-associated antigens. This program is generating compelling results in challenging cancers and is now at a development candidate stage demonstrating Phenomic’s ability to identify novel high-impact, druggable targets. ![](https://phenomic.ai/img/approach.png) ### Our Platform At Phenomic, we are pioneers in using advanced machine learning tools for processing imaging, RNA sequencing, and spatial transcriptomics data to understand the biology of single cells sitting in complex multi-cell systems. Our platform allows us to explore cell type and target expression profiles in exquisite detail, both in human cancer and normal tissue samples, as well as disease relevant experimental systems (e.g., human tumor explants, animal models). ### Team ![Girish Aakalu](https://phenomic.ai/img/team/girish.jpg) Girish Aakalu CEO Girish brings over two decades of biopharma industry experience to Phenomic. Prior to joining Phenomic, Girish held leadership roles at Genocea, Ipsen, Pfizer, and Genentech. He began his career at LEK Consulting’s life science practice. Girish received a PhD in Cellular and Molecular Neurobiology from Calte

Phenomic AI uses machine learning to analyze single-cell RNA data, aiding in the discovery of novel targets for solid tumor treatment.

Phenomic AI

Phenomic AI specializes in using advanced machine learning to process imaging, RNA sequencing, and spatial transcriptomics data, focusing on the intricate biology of single cells within complex multicellular systems. Their platform is designed to explore cell type and target expression profiles in great detail, aiding in the discovery of novel therapeutic targets for solid tumors. This approach enables the identification of high-impact, druggable targets, demonstrating the platform's potential in addressing challenging cancers.

Phenomic AI

Categories

Description

Summary

Use Cases

Platforms

Regulatory Status

API Available

Added to Directory

Target Customer

Contact